Shares of Fortress Biotech, Inc. (FBIO) surged Monday after the company announced a $205 million asset sale tied to a Rare Pediatric Disease Priority Review Voucher.
The stock is currently trading at $3.9698, up $0.6098 or 18.15%, on the Nasdaq. The stock opened at $3.7900 after closing Friday at $3.3600. The stock has traded between $1.3300 and $4.5300 in the past 52-week period. Trading volume soared far above average.
Fortress said its subsidiary Cyprium Therapeutics entered an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds. The voucher was granted following the FDA approval of ZYCUBO for Menkes disease in January 2026.
Cyprium remains eligible for royalties on ZYCUBO sales and up to $129 million in milestone payments.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.